(Q46433362)

22 December 2017

title

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose (English)

1 reference

22 December 2017

1 reference

3

1 reference

22 December 2017

author name string

Herman D

1

1 reference

22 December 2017

Locatelli I

2

1 reference

22 December 2017

Peternel P

4

1 reference

22 December 2017

Stegnar M

5

1 reference

22 December 2017

Mrhar A

6

1 reference

22 December 2017

Breskvar K

7

1 reference

22 December 2017

Dolzan V

8

1 reference

22 December 2017

publication date

1 January 2005

1 reference

22 December 2017

The Pharmacogenomics Journal

published in

1 reference

22 December 2017

volume

5

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

193-202

1 reference

22 December 2017

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Age as a determinant of sensitivity to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Inhibition selectivity of grapefruit juice components on human cytochromes P450

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Should clearance be normalised to body surface or to lean body mass?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

7 January 2021

CYP2C9*3 allelic variant and bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

7 January 2021

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

7 January 2021

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

7 January 2021

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500308

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500308

1 reference

22 December 2017

1 reference

22 December 2017